These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 23565638)

  • 1. Targeting platelet-neutrophil interactions in giant-cell arteritis.
    Baldini M; Manfredi AA; Maugeri N
    Curr Pharm Des; 2014; 20(4):567-74. PubMed ID: 23565638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiplatelet therapy to prevent ischemic events in giant cell arteritis: protocol for a systematic review and meta-analysis.
    Makhzoum JP; Baati Y; Tanase O; Mendel A; Pagnoux C; Ross C
    Syst Rev; 2024 Jul; 13(1):173. PubMed ID: 38978122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aspirin and P2Y12 Inhibitors in platelet-mediated activation of neutrophils and monocytes.
    Schrottmaier WC; Kral JB; Badrnya S; Assinger A
    Thromb Haemost; 2015 Aug; 114(3):478-89. PubMed ID: 25904241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigational analysis reveals a potential role for neutrophils in giant-cell arteritis disease progression.
    Nadkarni S; Dalli J; Hollywood J; Mason JC; Dasgupta B; Perretti M
    Circ Res; 2014 Jan; 114(2):242-8. PubMed ID: 24158630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [From pathogenesis of giant cell arteritis to new therapeutic targets].
    Samson M; Bonnotte B
    Rev Med Interne; 2017 Oct; 38(10):670-678. PubMed ID: 28800947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Silent, or masked, giant cell arteritis is associated with a strong inflammatory response and a benign short term course.
    Liozon E; Boutros-Toni F; Ly K; Loustaud-Ratti V; Soria P; Vidal E
    J Rheumatol; 2003 Jun; 30(6):1272-6. PubMed ID: 12784402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelets directly enhance neutrophil transmigration in response to oxidised low-density lipoprotein.
    Badrnya S; Butler LM; Söderberg-Naucler C; Volf I; Assinger A
    Thromb Haemost; 2012 Oct; 108(4):719-29. PubMed ID: 22836389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis.
    Nesher G; Berkun Y; Mates M; Baras M; Rubinow A; Sonnenblick M
    Arthritis Rheum; 2004 Apr; 50(4):1332-7. PubMed ID: 15077317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review: What Is the Current Evidence for Disease Subsets in Giant Cell Arteritis?
    van der Geest KSM; Sandovici M; van Sleen Y; Sanders JS; Bos NA; Abdulahad WH; Stegeman CA; Heeringa P; Rutgers A; Kallenberg CGM; Boots AMH; Brouwer E
    Arthritis Rheumatol; 2018 Sep; 70(9):1366-1376. PubMed ID: 29648680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenesis of giant-cell arteritis: how targeted therapies are influencing our understanding of the mechanisms involved.
    Terrades-Garcia N; Cid MC
    Rheumatology (Oxford); 2018 Feb; 57(suppl_2):ii51-ii62. PubMed ID: 29982777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenesis of giant cell arteritis: new insight into the implication of CD161+ T cells.
    Samson M; Audia S; Martin L; Janikashvili N; Bonnotte B
    Clin Exp Rheumatol; 2013; 31(1 Suppl 75):S65-73. PubMed ID: 23663684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Masked giant cell arteritis.
    Cheung PP; Richards G
    Aust Fam Physician; 2006 Nov; 35(11):893-5. PubMed ID: 17099811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Platelet-leukocyte deregulated interactions foster sterile inflammation and tissue damage in immune-mediated vessel diseases.
    Maugeri N; Baldini M; Ramirez GA; Rovere-Querini P; Manfredi AA
    Thromb Res; 2012 Mar; 129(3):267-73. PubMed ID: 22245222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Advances in Giant Cell Arteritis.
    Guevara M; Kollipara CS
    Curr Rheumatol Rep; 2018 Apr; 20(5):25. PubMed ID: 29611005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in our understanding of giant cell arteritis pathogenesis.
    Samson M; Corbera-Bellalta M; Audia S; Planas-Rigol E; Martin L; Cid MC; Bonnotte B
    Autoimmun Rev; 2017 Aug; 16(8):833-844. PubMed ID: 28564617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Giant cell arteritis--old questions, current answers].
    Bnaya A; Nesher G; Sonenblick M; Breuer GS
    Harefuah; 2014 Dec; 153(12):747-50, 751. PubMed ID: 25654918
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Giant-cell arteritis and polymyalgia rheumatica.
    Weyand CM; Goronzy JJ
    Ann Intern Med; 2003 Sep; 139(6):505-15. PubMed ID: 13679329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of drugs acting on platelet and neutrophil aggregation depending on their interaction.
    Akopov S; Grigorian M; Gabrielian E
    Methods Find Exp Clin Pharmacol; 1991 Nov; 13(9):591-4. PubMed ID: 1787765
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective evaluation of the relationship between platelet-leukocyte conjugate formation and recurrent myocardial ischemia in patients with acute coronary syndromes.
    Faraday N; Braunstein JB; Heldman AW; Bolton ED; Chiles KA; Gerstenblith G; Schulman SP
    Platelets; 2004 Feb; 15(1):9-14. PubMed ID: 14985171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High incidence of severe ischaemic complications in patients with giant cell arteritis irrespective of platelet count and size, and platelet inhibition.
    Berger CT; Wolbers M; Meyer P; Daikeler T; Hess C
    Rheumatology (Oxford); 2009 Mar; 48(3):258-61. PubMed ID: 19129348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.